Project Grant R01CA293602
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$432K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $627,272 to The Johns Hopkins University to optimize the efficacy of chimeric antigen receptor (CAR) T cells against pancreatic tumors. The project aims to engineer self-propelled, tumor-infiltrating CAR T cells using synthetic cytokine receptors (known as "velocity receptors") that enhance the migration speed and tumor infiltration of the CAR T cells. The research will test...
This federal Project Grant award for $138,742 from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports research to investigate alterations in cellular communication networks in pancreatic ductal adenocarcinoma (PDAC) in response to immunotherapy treatments. The primary objectives are to: 1) develop statistical methods to analyze single-cell RNA sequencing data to identify cellular interactions that differ between immunotherapy treatment groups in...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research on the role of the enzyme JMJD4 in pancreatic cancer. The $145,000 award to the University of Oklahoma Health Sciences Center will fund two specific aims: (I) determining the role of JMJD4 in pancreatic cancer cells, and (II) revealing how JMJD4 acts at the molecular level, particularly through interactions with the transcription factors NRF2 and HIF-2A. The research seeks to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $698,008 to The Trustees of the University of Pennsylvania to conduct research on the metabolic and epigenetic mechanisms underlying pancreatic ductal adenocarcinoma (PDA), a deadly form of cancer. The research aims to elucidate how branched-chain amino acid (BCAA) metabolism regulates histone propionylation, a chromatin modification associated with gene activation, and how this...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $432,889 to The Johns Hopkins University to advance the understanding and treatment of cachexia, a severe wasting condition associated with pancreatic ductal adenocarcinoma (PDAC). The project aims to: 1) study the effects of downregulating key genes involved in glutamine metabolism on cachexia, tumor, and organ metabolism using imaging and...
The National Cancer Institute (NCI) awarded a $269,280 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Translational Genomics Research Institute (TGen) to conduct research aimed at improving the treatment of pancreatic ductal adenocarcinoma (PDAC). The project will evaluate the biological effects and antitumor activity of a senescent cell-targeted antibody, SIWA318, in preclinical PDAC models. Specifically, the research will determine if SIWA318 can remodel the tumor...
This federal Project Grant award of $360,413.00, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by The Johns Hopkins University focused on early hepatic dissemination of pancreatic cancer. The research aims to evaluate the efficacy of systemic chemotherapy-enhanced alpha-particle radiotherapy as a treatment approach. The award has a performance period from November 1, 2024 to October 31, 2027. As a leading academic...
This $867,712 Project Grant award from the Department of the Army Medical Command (under the Military Medical Research and Development program, CFDA 12.420) supports advanced biomedical research at The Johns Hopkins University focused on transforming healthcare for military service members and the general public. The research aims to investigate effective treatment of pancreatic cancer through systemic chemotherapy combined with alpha-particle radiotherapy, with a focus on early hepatic...
The National Cancer Institute awarded a $342,102 Project Grant (CFDA 93.398 - Cancer Research Manpower) to The Johns Hopkins University to elucidate the role of the chromatin regulator HMGA1 in KMT2A-rearranged acute myeloid leukemia (AML). The research aims to define how HMGA1 drives leukemogenesis and chemoresistance in this aggressive form of AML, and determine how HMGA1 induces the expression of key leukemogenic HOX genes and represses the CDKN1A tumor suppressor. This 2.25-year project,...
The Johns Hopkins University will receive $620,588 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund research to develop a 3D multiscale analysis of malignant progression in human pancreatic cancer. Through September 2025, researchers will investigate medical solutions for pancreatic cancer at the cellular and tissue levels to transform understanding and treatment of this...